Cantor Fitzgerald Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $101
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $98 to $101.
November 03, 2023 | 4:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Intra-Cellular Therapies and raised the price target from $98 to $101.
The news of Cantor Fitzgerald maintaining an Overweight rating and raising the price target for Intra-Cellular Therapies is likely to be seen as a positive signal by the market, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100